Thomas A. Bayer

16.5k total citations
246 papers, 12.9k citations indexed

About

Thomas A. Bayer is a scholar working on Physiology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Thomas A. Bayer has authored 246 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Physiology, 63 papers in Cellular and Molecular Neuroscience and 52 papers in Molecular Biology. Recurrent topics in Thomas A. Bayer's work include Alzheimer's disease research and treatments (127 papers), Nuclear Receptors and Signaling (30 papers) and Neuroscience and Neuropharmacology Research (28 papers). Thomas A. Bayer is often cited by papers focused on Alzheimer's disease research and treatments (127 papers), Nuclear Receptors and Signaling (30 papers) and Neuroscience and Neuropharmacology Research (28 papers). Thomas A. Bayer collaborates with scholars based in Germany, United States and Switzerland. Thomas A. Bayer's co-authors include Oliver Wirths, Gerd Multhaup, Peter Falkai, Jens Ove Andreasen, Sadim Jawhar, Konrad Beyreuther, Hans Ulrik Paulsen, Yu Zhou, Christian Czech and Laurent Pradier and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Thomas A. Bayer

239 papers receiving 12.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Thomas A. Bayer 6.9k 4.3k 2.6k 2.1k 1.6k 246 12.9k
Daniel W. McKeel 9.9k 1.4× 4.4k 1.0× 2.3k 0.9× 2.9k 1.4× 1.2k 0.8× 82 16.5k
Sam Gandy 13.2k 1.9× 8.1k 1.9× 3.7k 1.4× 2.8k 1.3× 3.3k 2.1× 292 21.5k
Carol A. Colton 3.4k 0.5× 3.2k 0.7× 1.9k 0.7× 3.2k 1.5× 662 0.4× 180 11.8k
Allen D. Roses 17.9k 2.6× 14.4k 3.4× 5.7k 2.2× 3.8k 1.8× 3.5k 2.2× 357 34.7k
Lars Bertram 6.1k 0.9× 5.3k 1.2× 2.0k 0.8× 1.5k 0.7× 1.2k 0.8× 172 13.0k
Ann C. McKee 5.0k 0.7× 5.1k 1.2× 2.9k 1.1× 2.6k 1.3× 793 0.5× 236 22.3k
Gerald A. Higgins 5.7k 0.8× 4.0k 0.9× 2.6k 1.0× 1.2k 0.6× 1.5k 1.0× 93 10.8k
Jin‐Moo Lee 3.8k 0.6× 4.0k 0.9× 2.7k 1.0× 2.6k 1.2× 749 0.5× 337 15.7k
James A. R. Nicoll 7.3k 1.1× 4.8k 1.1× 2.4k 0.9× 5.2k 2.5× 1.3k 0.8× 224 17.0k
Richard S. Jope 3.3k 0.5× 12.8k 3.0× 6.6k 2.5× 1.5k 0.7× 1.8k 1.2× 251 23.0k

Countries citing papers authored by Thomas A. Bayer

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Bayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Bayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Bayer more than expected).

Fields of papers citing papers by Thomas A. Bayer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Bayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Bayer. The network helps show where Thomas A. Bayer may publish in the future.

Co-authorship network of co-authors of Thomas A. Bayer

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Bayer. A scholar is included among the top collaborators of Thomas A. Bayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Bayer. Thomas A. Bayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bouter, Caroline, et al.. (2025). Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice. Journal of Alzheimer s Disease Reports. 9. 4123423378–4123423378.
2.
Rieke, K., Thomas A. Bayer, Jennifer L. Sullivan, et al.. (2025). Strategies and Outcomes of Age-Friendly Health System Implementation in Outpatient Settings: A Systematic Review. INQUIRY The Journal of Health Care Organization Provision and Financing. 62. 2886911972–2886911972. 1 indexed citations
3.
Bozzay, Melanie L., Lan Jiang, Alyssa N. De Vito, et al.. (2024). Time to Dementia Diagnosis Among Veterans with Comorbid Insomnia and Depressive Episodes. Journal of Alzheimer s Disease. 100(3). 899–909. 1 indexed citations
4.
Bayer, Thomas A., et al.. (2023). Simplification of contour lines, based on axial splines, with high-quality results. International Journal of Geographical Information Systems. 37(7). 1520–1554. 1 indexed citations
5.
Behan, Michael, et al.. (2022). Complex reconstruction of iatrogenic skew foot deformity. BMJ Case Reports. 15(3). e248639–e248639. 1 indexed citations
6.
Bayer, Thomas A., et al.. (2022). Spinal epidural lipomatosis and focal posterior longitudinal ligament hypertrophy causing severe cauda equina crowding. BMJ Case Reports. 15(9). e250112–e250112. 2 indexed citations
7.
Bouter, Yvonne, et al.. (2022). Donanemab detects a minor fraction of amyloid-β plaques in post-mortem brain tissue of patients with Alzheimer’s disease and Down syndrome. Acta Neuropathologica. 143(5). 601–603. 17 indexed citations
8.
Bayer, Thomas A., et al.. (2022). Ablation of the Presynaptic Protein Mover Impairs Learning Performance and Decreases Anxiety Behavior in Mice. International Journal of Molecular Sciences. 23(19). 11159–11159. 2 indexed citations
9.
Bayer, Thomas A.. (2021). Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease. Molecular Psychiatry. 27(4). 1880–1885. 66 indexed citations
10.
Bakrania, Preeti, Yvonne Bouter, Caroline Bouter, et al.. (2021). Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease. Molecular Psychiatry. 27(2). 840–848. 21 indexed citations
11.
Lutter, Christoph, Rolf Janka, Stefanie Küerten, et al.. (2021). MRI of Finger Pulleys at 7T—Direct Characterization of Pulley Ruptures in an Ex Vivo Model. Diagnostics. 11(7). 1206–1206. 6 indexed citations
12.
13.
Hüttenrauch, Melanie, et al.. (2015). Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. Journal of Alzheimer s Disease. 44(4). 1291–1302. 65 indexed citations
14.
Wirths, Oliver, Christian Erck, Henrik Martens, et al.. (2010). Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease. Journal of Biological Chemistry. 285(53). 41517–41524. 91 indexed citations
15.
Rutten, Bart P. F., Nicolien M. van der Kolk, S Schäfer, et al.. (2005). Age-Related Loss of Synaptophysin Immunoreactive Presynaptic Boutons within the Hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L Transgenic Mice. American Journal Of Pathology. 167(1). 161–173. 97 indexed citations
16.
Beasley, Clare L., William G. Honer, Klaus von Bergmann, et al.. (2005). Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disorders. 7(5). 449–455. 100 indexed citations
17.
Bayer, Thomas A., et al.. (1999). Increased oncogenicity of subclones of SV40 large T-induced neuroectodermal tumor cell lines after loss of large T expression and concomitant mutation in p53.. PubMed. 59(8). 1980–6. 26 indexed citations
18.
Bayer, Thomas A., et al.. (1997). Daimler Benz Research : System and experiments routing and filtering. Text REtrieval Conference. 329–346. 3 indexed citations
19.
Schürmann, Jürgen, et al.. (1995). Document analysis—from pixels to contents. IEEE Computer Society Press eBooks. 403–421. 23 indexed citations
20.
Bayer, Thomas A.. (1992). Representing and Utilising Knowledge for Understanding Structured Documents. Machine Vision and Applications. 75–78. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel W. McKeel Breakdown of academic impact, for papers by Sam Gandy Breakdown of academic impact, for papers by Carol A. Colton Breakdown of academic impact, for papers by Allen D. Roses Breakdown of academic impact, for papers by Lars Bertram Breakdown of academic impact, for papers by Ann C. McKee Breakdown of academic impact, for papers by Gerald A. Higgins Breakdown of academic impact, for papers by Jin‐Moo Lee Breakdown of academic impact, for papers by James A. R. Nicoll Breakdown of academic impact, for papers by Richard S. Jope
Rankless by CCL
2026